PUBLIC COMPANY
saveNovo Nordisk Inc
updated 4mo ago
Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd. Novo Nordisk is controlled by majority shareholder Novo Holdings A/S which holds approximately 28.1% of its shares and a majority (77.1%) of its voting shares.
community read0 votes
🐶 often sniffed alongside
top 8- tagApproval78 co-mentions · 39 sources
- drugVICTOZA59 co-mentions · 30 sources
- drugLIRAGLUTIDE30 co-mentions · 30 sources
- drugSaxenda30 co-mentions · 30 sources
- drugOzempic23 co-mentions · 4 sources
- drugWegovy23 co-mentions · 4 sources
- drugWegovy Pill22 co-mentions · 3 sources
- drugSOGROYA18 co-mentions · 9 sources
pipeline
16
marketed
15
phase 3
0
catalysts ytd
4
approvals ytd
3
recalls ytd
0
Pipeline(16)
view full pipeline →pipeline depth16 products
15Marketed1Unknown
Marketed
(estradiol + norethindrone)
Atrophic Vaginitis (Vaginal Atrophy/Vulvovaginal Atrophy/…
Marketed(insulin aspart + insulin aspart protamine)
Type 1 Diabetes (Juvenile Diabetes)
Marketed(insulin degludec + liraglutide)
Type 2 Diabetes
Marketed(insulin human + insulin isophane)
Type 1 Diabetes (Juvenile Diabetes)
MarketedFiasp
Type 1 Diabetes (Juvenile Diabetes)
MarketedRybelsus
Cardiovascular Risk Factors
MarketedSaxenda
Obesity
MarketedWegovy Pill
type 2 diabetes, cardiovascular risk reduction
Marketedcoagulation factor IX (recombinant), glycopegylated LA
Hemophilia B (Factor IX Deficiency)
Marketedcoagulation factor XIII A-subunit (recombinant)
Fibrin Stabilizing Factor Deficiency (Factor XIII Deficie…
Marketedconcizumab
Hemophilia A (Factor VIII Deficiency)
Marketeddasiglucagon
Hypoglycemia
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →🐶 Hiring Signal
News
- Foghorn cuts 40% of workforceFollow along as BioSpace tracks job cuts and restructuring initiatives.biospace · 1d ago
- Kailera, Hengrui’s GLP-1/GIP candidate delivers weight, menstrual benefits to women with PMOSKailera Therapeutics and Hengrui Pharma’s weekly injection showed benefits beyond weight loss in a mid-stage trial, leading to more regular menstrual cycles in patients with polyendocrine metabolic…biospace · 1d ago
- Mistrust in science and a juicy gene-editing lawsuitWhy have so many Americans lost trust in science? And what's the deal with a new gene-editing lawsuit? Find out on this week's episode of "The Readout LOUD" podcast.stat · 2d ago
- #EASD26: Regeneron's antibody helps patients regain muscle after stopping GLP-1 therapyMILAN — Regeneron’s investigational drug helped obesity patients who stopped taking Novo’s Wegovy regain a similar amount of muscle mass to what they lost when they took the GLP-1, according to new…endpoints · 2d ago
- The top 12 companies hiring in biopharma nowLooking for a biopharma job? Check out the BioSpace list of 12 top companies hiring life sciences professionals like you.biospace · 3d ago
- STAT+: Eli Lilly’s Zepbound combined with amylin drug led to significant weight loss in mid-stage trialAn investigational combination therapy from Eli Lilly led to significant weight loss in a mid-stage study, but high discontinuation rates raise questions about tolerability.stat · 3d ago
- Lilly builds commercial case for GLP-1 products over Novo with indirect analysesEli Lilly’s weight loss pill Foundayo has had a “slower-than-hoped” launch, according to BMO Capital Markets, which contended that the indirect comparison data—despite falling short of definitive p…biospace · 3d ago
- Roche cuts muscle-sparing obesity drug after mid-stage disappointmentRoche’s anti-myostatin therapy emugrobart is unlikely to elicit meaningful weight loss, according to an interim mid-stage analysis, prompting the pharma to return the asset rights to its subsidiary…biospace · 4d ago
- Novo adds long-term obesity differentiation in up to $2.6B Hengrui dealInvestors looking for more transformative business development at Novo will have to wait, but a new partnership with China’s Hengrui Pharma adds a new weekly oral option to the Danish pharma’s earl…biospace · 4d ago
- Novo to spend $300M upfront to license Hengrui's weekly oral weight loss drugNovo has signed its fourth weight loss-focused pact of the year, this time tapping a preclinical GLP-1/GIP receptor agonist from China’s Hengrui that could be dosed as little as once a week. The Da…endpoints · 4d ago
Data sources
Found something off?
comments(0)
5-min edit window · permanent after that